Management of the open labyrinth.
Labyrinthine fistulas occur in approximately 5% of cholesteatoma cases, but the management of this difficult problem remains controversial. This study assessed the preoperative presentation and outcome in 37 patients operated on for cholestatoma complicated by labyrinthine fistula. Therapy involved removing the matrix from each fistula and reconstructing the bony wall of the labyrinth with bone dust, fibrin glue, and perichondrium. Corticosteroids were added to the management protocol in more recent cases. A fistula classification scheme was introduced to standardize the reporting of the extent of labyrinthine involvement and results of treatment. The most common preoperative symptoms, sensorineural hearing loss and vertigo, were notably lacking in more than 30% of patients. The fistula test was positive in only 32% of cases. Corticosteroids were seen to have a beneficial impact on postoperative outcome in those cases involving injury to the membranous labyrinth or removal of perilymph.
Dornhoffer
J L
JL
Department of Otolaryngology, Julius Maximilians University, Wuerzburg, Germany.
Milewski
C
C
D016025:Bone Transplantation; D002356:Cartilage / Q000637:transplantation; D018424:Cholesteatoma, Middle Ear / Q000150:complications* / Q000601:surgery; D005260:Female; D015718:Fibrin Tissue Adhesive; D005402:Fistula / Q000145:classification / Q000209:etiology / Q000601:surgery*; D006309:Hearing / Q000502:physiology; D006319:Hearing Loss, Sensorineural / Q000209:etiology; D006801:Humans; D007759:Labyrinth Diseases / Q000209:etiology / Q000601:surgery*; D008297:Male; D009759:Nystagmus, Pathologic / Q000209:etiology; D010498:Perilymph; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D014717:Vertigo / Q000209:etiology
D015718:Fibrin Tissue Adhesive; D011239:Prednisolone